Promontory Therapeutics Presents Safety and Efficacy Data of PT-112 in Combination with PD-L1 Inhibition in Treatment of Advanced Non-Small Cell Lung Cancer at ESMO I-O 2022
Data suggest that PT-112 and PD-L1 combination is well-tolerated and has meaningful clinical benefits in pretreated patients without known predictive markers for immunotherapy response